Molzym Announces Double-Digit Million EUR Capital Increase

07-Jul-2022 - Germany

Molzym is proud to announce a double-digit million EUR investment by a large single family office.

The capital will be deployed for the international business expansion, in particular for market entry and expansion in the US and China as well as further expanding its presence in Europe. Furthermore, funds will be used for market launch of its next generation diagnostic tests “AutoSepT” targeting the Sepsis market and delivering results directly from sample within 3 hours.

Molzym is also glad to announce the formation of a new Supervisory Board with its new Chairwoman Veronika Clarici-Fanfule. The company also welcomes Dr. Kerstin Waterloh, Dr. Georg Lautscham, Dr. Gerhard Ries and Vladimir Soha to the board, who all bring solid experience in the MedTech and Diagnostics market.

Over the past years, Molzym has steadily and organically build up a strong and unique molecular diagnostic expertise with its highly experienced and scientific team. In recent months, the team has been complemented by international commercial and operational expertise. With the additional funds, the Molzym team will further grow. Gabriel Tirouflet, CEO of Molzym says: “For the first time since its creation, Molzym gathered the financial means to achieve its ambitions. With MolYsis™, the only validated microbial DNA isolation technology, Molzym has a unique opportunity to establish itself as a reference for both broad-spectrum PCR and NGS sample preparation. The future of the company is built on these two pillars”

Veronika Clarici-Fanfule, Chairwoman of the new Supervisory Board, emphasizes Molzym’s unique role in the application of NGS to infectious diseases: “One of the key challenges to sustain and even expedite the impressive growth of NGS and metagenomics in the context of microbial infection diagnosis and antimicrobial resistance detection is the importance of human DNA depletion from clinical samples. This inherent market need represents a tremendous opportunity to Molzym and its MolYsis™ technology. The new financing round will enable the company to leverage its unique position to penetrate this market and establish itself as one of its key player”.

https://www.bionity.com/en/news/1176817/molzym-announces-double-digit-million-eur-capital-increase.html